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INTRODUCTION
Tigecycline is an injectable antibacterial agent
derived from the tetracyclines and classiﬁed by
the manufacturer as a glycylcycline. Tigecycline
was registered by the European Medicines
Agency (EMEA) in May 2006 for parenteral use
in complicated skin and skin-structure infections
(CSSSIs) and complicated intra-abdominal infec-
tions (CIAIs) caused by Enterobacteriaceae (ex-
cept Proteus spp., Morganella spp. and Providencia
spp.), staphylococci, streptococci, Enterococcus fae-
calis and Enterococcus faecium. Tigecycline is active
against microorganisms that have developed
resistance to existing tetracyclines. This Technical
Note is based on the EUCAST tigecycline ration-
ale document (available on the EUCAST website:
http://www.eucast.org). The rationale document
includes more details and published references
relating to the selection of EUCAST breakpoints.
DOSAGE
Clinical breakpoints have been determined for the
parenteral use of tigecycline 100 mg followed by
50 mg every 12 h in CSSSI and CIAI. Tigecycline
has not been licensed previously in Europe, so
there is no history of differences in dosages
among European countries.
MIC DISTRIBUTIONS
The tigecycline MIC values for wild-type staphy-
lococci, streptococci, Ent. faecalis and Ent. faecium
are £0.5 mg ⁄L. The corresponding values for
Escherichia coli, Klebsiella spp., Citrobacter spp.,
Salmonella spp. and Shigella spp. are £2 mg ⁄L; for
Proteus spp., Morganella spp. and Providencia spp.
they are £8 mg ⁄L; and for Pseudomonas spp. they
are >2 mg ⁄L. Many Acinetobacter spp. are inhib-
ited by £1 mg ⁄L, but evidence of clinical efﬁcacy
is insufﬁcient (for wild-type MIC distributions,
see http://www.eucast.org). All MIC values were
from tests in freshly prepared medium, which is
required to avoid loss of activity of tigecycline in
broth.
ESTABLISHED BREAKPOINTS
None of the European breakpoint committees had
established breakpoints for tigecycline before the
establishment of the EUCAST breakpoint.
PHARMACOKINETIC DATA
Based on a standard parenteral dose of 100 mg
followed by 50 mg every 12 h, the pharmacoki-
netic data used to evaluate tigecycline are shown
in Table 1.
PHARMACODYNAMIC DATA
The pharmacodynamics of tetracyclines are not
fully understood. They are modestly bactericidal
with persistent antimicrobial effects. Limited ani-
mal data indicate that AUC ⁄MIC is the pharmaco-
dynamic index best related to outcome. Studies in
humans indicate a relationship between AUC/
MIC and clinical as well as microbiological
efﬁcacy. However, these data are not always easy
to interpret because of surgical intervention and
mixed bacterial infections. The CART breakpoints
(AUC/MIC ratios that discriminate between
Corresponding author and reprint requests: G. Kahlmeter,
Klinisk mikrobiologi, Centrallasarettet, 351 85 Va¨xjo¨, Sweden
E-mail: gunnar.kahlmeter@ltkronoberg.se
*G. Kahlmeter (chairman), D. F. J. Brown (scientiﬁc
secretary), R. Canton (clinical data co-ordinator), A. P.
MacGowan (BSAC, UK), J. W. Mouton (CRG, The Neth-
erlands), A. Rodloff (DIN, Germany), F. Goldstein (CA-
SFM, France), I. Odenholt (SRGA, Sweden), M. Steinbakk
(NWGA, Norway), P. Varaldo (Italy, for EUCAST General
Committee), W. Hryniewicz (Poland, for EUCAST General
Committee).
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
populations with a good response and those with
a poor response) obtained from human trials with
CSSSIs and CIAIs were 12.5 and 6.96, respec-
tively. Monte Carlo simulations using these
values indicate that pharmacokinetic ⁄pharmaco-
dynamic breakpoints of £0.25 mg ⁄L and
£0.5 mg ⁄L are appropriate for Staphylococcus
aureus and Esch. coli, respectively.
CLINICAL EFFICACY
Tigecycline efﬁcacy studies have been performed
in CSSSI and CIAI. In the two CSSSI studies,
tigecycline showed clinical and microbiological
non-inferiority to the comparator agents (vanco-
mycin plus aztreonam), and the most common
isolates were Staph. aureus, Streptococcus pyogenes,
Esch. coli and Ent. faecalis. In two CIAI trials,
tigecycline again showed clinical and microbio-
logical non-inferiority to the comparator agent
(imipenem), and the most common isolates were
Esch. coli, Bacteroides fragilis group, Streptococcus
anginosus, Klebsiella pneumoniae and Ent. faecalis.
BREAKPOINTS
Breakpoints are summarised in Table 2.
Non-species-related breakpoints
Non-species-related breakpoints have been deter-
mined mainly on the basis of pharmacokinetic ⁄
pharmacodynamic data and are independent of
MIC distributions for speciﬁc species. They are for
use only with species that have not been given a
species-speciﬁc breakpoint, and not with those
species for which susceptibility testing is not
recommended (marked with ‘–’ or IE in EUCAST
breakpoint tables). Although incomplete, phar-
Table 1. Pharmacokinetic data for tigecycline
Parameter
Pharmacological studies
Efﬁcacy studies
50 mg100 mg 50 mg
Cmax (mg ⁄L)
30-min infusion 1.45 ± 0.32 0.87 ± 0.23 0.80 ± 0.46
60-min infusion 0.90 ± 0.27 0.63 ± 0.10 0.49 ± 0.28
Cmin (mg ⁄L) NA 0.13 ± 0.08 0.16 ± 0.09
Total body clearance (L ⁄h) 21.8 ± 8.9 23.8 ± 7.8 19.9 ± 8.1
T1 ⁄ 2 (h) 27.1 ± 14.3 42.4 ± 35.3 NA
AUC24 h (mg ⁄L.h) NA 4.70 ± 1.70 5.85 ± 2.48
AUC¥ (mg ⁄L.h) 5.19 ± 1.86 NA NA
Fraction unbound (%) 13–29 13–20 NA
Volume of distribution (L) 568 ± 244 639 ± 307 NA
NA, not available.
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macodynamic data suggest non-species-related
breakpoints in the region of susceptible (S) £0.25
and resistant (R) >0.5 mg ⁄L for tigecycline.
Species-related breakpoints
A susceptible breakpoint of 0.25 mg ⁄L for strep-
tococci and enterococci, and of 0.5 mg ⁄L for
staphylococci, would render wild-type staphylo-
cocci, streptococci and enterococci susceptible to
tigecycline. This would be reasonably compatible
with pharmacokinetic, pharmacodynamic and
clinical data, and would not split wild-type
populations. Resistant isolates are rare or non-
existent, and it is recommended that the identi-
ﬁcation and antimicrobial susceptibility tests are
repeated for strains with MIC values above the
S ⁄ I breakpoint; if the result is conﬁrmed, the
isolate should be sent to a reference laboratory.
Until there is evidence regarding clinical response
for conﬁrmed isolates with MICs above the
current resistant breakpoint, they should be
reported as resistant.
There is clinical evidence to suggest that wild-
type Esch. coli, Klebsiella spp. and Enterobacter spp.
respond to tigecycline therapy. A susceptible
breakpoint of 1 mg ⁄L would render wild-type
Enterobacteriaceae (except Proteus spp., Morgan-
ella spp. and Providencia spp., which have higher
MIC values and a doubtful clinical response)
susceptible to tigecycline and largely undivided
by the breakpoint.
Species without breakpoints
For anaerobic bacteria, there is clinical evidence of
activity in mixed intra-abdominal infections, but
no correlation between MIC values, pharmacoki-
netic ⁄pharmacodynamic data and clinical out-
come. Therefore, no breakpoint for susceptibility
testing is given.
For Acinetobacter spp., Haemophilus inﬂuenzae,
Moraxella catarrhalis, Neisseria spp. and Streptococ-
cus pneumoniae, the MIC values imply that infec-
tions with these organisms might be treated with
tigecycline, but the clinical evidence is currently
limited and these organisms are not within the
approved indications. Tigecycline has reduced
activity against Proteus spp., Morganella spp.,
Providencia spp. and Pseudomonas spp. These
organisms have not been allocated breakpoints,
and laboratories are advised not to test these
genera.
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